This article is more than 5 years old. Information may no longer be current.
K2M launches expanded biologics portfolio
Click Here to Manage Email Alerts
K2M Inc. announced an expansion of the company’s biologics offering with the launch of its VESUVIUS Osteobiologic Systems and new additions to its VIKOS Allograft Systems.
According to a company press release, the VESUVIUS is designed to enhance bone regeneration after spine surgery and in a variety of configurations and sizes. VESUVIUS Demineralized Fibers and Sponge are treated with LifeNet Health’s patented ALLOWASH XG sterilization process and PAD demineralization technology to protect bone morphogenetic proteins, while ensuring optimal osteoinductivity.
The LifeNet Health relationship also enables K2M to extend its existing VIKOS cervical offering to include unicortical, tricortical, and iliac crest grafts, as well as add two new product lines, VIKOS Void Fillers and VIKOS Shafts, according to the release. VIKOS has been designed to enhance osteoconductivity after spine surgery and, features the ALLOWASH XG process and PRESERVON technology for storage at ambient temperature.
“We are excited to further our relationship with LifeNet Health to dramatically grow our company’s presence in the $1.8 billion U.S. biologics sector and meet a significant demand for the high-quality products that surgeons have come to expect from K2M,” Eric Major, president and chief executive officer of K2M, stated in the release.